Results 121 to 130 of about 5,881 (166)

Exportin 1 inhibitor KPT‑330 reverses oxaliplatin resistance via p53 nuclear retention in colorectal cancer. [PDF]

Int J Mol Med
Lai C, Jia X, Chen Y, Chen K, Wang F, Zhang Q, Xiang X, Chen ZS, Xu L, Dai S.   +9 more
europepmc   +1 more source

Marked for Success: How RNA m⁶A Methylation Fine-Tunes Gut Epithelial Function. [PDF]

Cell Mol Gastroenterol Hepatol
Danan CH, Yannuzzi I, Hamilton KE.
europepmc   +1 more source

Advances in first-line treatment for primary central nervous system lymphoma: highlights from the 2025 ASH annual meeting. [PDF]

J Hematol Oncol
Wei R, Yang S.
europepmc   +1 more source

Detection of <i>XPO1</i>^E571K Gene Mutation from Cell-Free DNA in Blood Circulation of Lymphoma Patients by FAST-COLD PCR. [PDF]

Int J Mol Sci
Duangmano S, Viriyaadhammaa N, Khamphikham P, Intasai N, Tantiworawit A, Daroontum T, Chiampanichayakul S, Anuchapreeda S.   +7 more
europepmc   +1 more source

Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney. [PDF]

Front Pediatr
Yao Z, Zhanghuang C, Zhou N, Li J, Hao Z, Yan B, Zhao H.   +6 more
europepmc   +1 more source

LRRC59 cooperates with nuclear transporters to restrain the nuclear envelope repair machinery and safeguard genome integrity. [PDF]

Nat Commun
Timmer R, Bellanger A, Peeters S, Kim H, de la Ballina LR, Eikvar S, Arns AJ, Oortgijs E, Sekulić N, De Vos WH, Campsteijn C.   +10 more
europepmc   +1 more source

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis. [PDF]

Ann Med
Tan S, Li Y, Cao Y, Sun W, Hui W.
europepmc   +1 more source

Disparate leukemia mutations converge on nuclear phase-separated condensates. [PDF]

Cell
Datar GK, Khabusheva E, Anand A, Beale J, Sadek M, Chen CW, Potolitsyna E, Alcantara-Contessoto N, Liu G, De La Fuente J, Dollinger C, Guzman A, Martell A, Wohlan K, Maiti A, Short NJ, Yi SS, Andresen V, Gjertsen BT, Falini B, Rau RE, Brunetti L, Sahni N, Goodell MA, Riback JA.   +24 more
europepmc   +1 more source

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma. [PDF]

Cancer Med
Spriano F, Cascione L, Tarantelli C, Sartori G, Arribas AJ, Velasova A, Napoli S, Havranek O, Toretsky JA, Bertoni F.   +9 more
europepmc   +1 more source

XPO1 inhibition in KRAS-mutant cancers: time for clinical trials but how? [PDF]

Transl Lung Cancer Res
Nagasaka M, Khan HY, Luo F, Al-Hallak MN, Saif MW, Mohammad RM, Azmi AS.   +6 more
europepmc   +1 more source